Christopher A. Viehbacher, Chief Executive Officer of Sanofi said: 'During his many years with Sanofi, Hanspeter has made an exceptional contribution to the success of the Group and has helped bring Sanofi to the forefront of the industry. He has been a key member of the Executive Committee which has transformed Sanofi as a healthcare leader. His early recognition of growing opportunities in the emerging markets has contributed to the building of Sanofi's leading position there. With the Group now having an outlook of long term sustainable growth, I would like to sincerely thank Hanspeter for his leadership, commitment and energy and wish him the very best for the future'.

Hanspeter Spek joined the Group in 1985 as Marketing Director with Sanofi Pharma GmbH Germany. Throughout his tenure, he worked his way right up through the Group and was appointed to his current position as President, Global Operations in November 2009. He has been instrumental in the evolution of the Group, contributing to the significant success of flagship products such as Plavix®, Lantus® and Taxotere®, and has always been an inspirational leader and a key player in the various partnerships Sanofi has entered into and the integrations of Synthelabo in 1999, Aventis in 2004 and more recently Chattem and Merial. Hanspeter Spek will retain his role as Chairman of the Supervisory Board of Sanofi GmbH Germany during a transitional period.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).